5 in 10.000 or Real Chance of Early Relapse Detection

The Next Generation Chimerism Analysis for Higher Sensitivity Patients are going to benefit of considerably better healing opportunity as well as a tremendously increase of health-related quality of life.

Dresden, Germany, May 01, 2013 -- During this year’s EBMT-meeting held in London, a new, high-resolution diagnostics for the area of stem cell transplantation and leukemic diseases was launched by Biotype Diagnostic from Dresden. Combining two methods of analysis that are used traditionally in biotechnology, the company has developed a product, which allows detecting only 5 diseased blood cells in 10,000 healthy cells. When compared to standard methods used so far, this is in accordance with an increased sensitivity by a factor of 20. Physicians might notice signs that signify imminent relapse earlier, and, immediately can interfere therapeutically. The patients benefit is a considerably better healing opportunity as well as health-related quality of life can be increased tremendously.

Stem cell transplantation is a treatment that is used mainly for various forms of blood cancers. The sick or injured blood stem cells are replaced by healthy donor stem cells to extend the lives of patients suffering from leukaemia. Sometimes, due to this treatment, the life-threatening disease can even be overcome. To monitor success of stem cell transplantation and transplant engraftment, molecular methods are deployed, which measure the ratio between healthy donor and patients leukemic cells.

This measurement was so far accomplished with semi-quantitative methods that could determine the respective ratio only up to about 2-5 % accuracy. In contrast, analyses now can exactly succeed 0.05 %. The choice of used technologies ensures high sensitivity and hence the predictive value of the diagnosis. As a result, threatening relapse following stem cell transplantation, which is by means a highly stressful and risky treatment for patients, can be recognized earlier, and, might even be prevented.

About Biotype diagnostic:
Biotype Diagnostic GmbH develops molecular in-vitro diagnostics (IVD) for medical areas such as haematology/oncology and dermatology. The company thereby draws back on many years of experience in the development and production of test systems in the DNA analysis. In close collaboration with academic and clinical partners Biotype continuously transfer scientific know-how into marketable applications to create holistic diagnostics. Recently, the company’s portfolio was extended by DNA-extraction systems, which allow sample preparation of diverse biological liquids and tissues.

Contact:
Dr. Sophia Mersmann
Biotype Diagnostic
Moritzburger Weg 67
01109 Dresden, Germany
+49 351 8838 432
s.mersmann@biotype.de
http://www.biotype.de

This release was published on openPR.